Influenza virus vaccine oral - Vaxcel

Drug Profile

Influenza virus vaccine oral - Vaxcel

Latest Information Update: 30 Jun 1999

Price : $50

At a glance

  • Originator Vaxcel [CEASED]
  • Developer Southern Research Institute; Vaxcel [CEASED]
  • Class Influenza virus vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Influenza virus infections

Most Recent Events

  • 30 Jun 1999 Discontinued-I for Influenza virus infections in USA (PO)
  • 25 Jun 1998 Zynaxis is now called Vaxcel
  • 17 Oct 1995 Secretech is now called Zynaxis
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top